Randomized trial on acute toxicities of weekly vs three‐weekly cisplatin‐based chemoradiation in head and neck cancer

BACKGROUND: The current first‐line treatment of locally advanced head and neck carcinoma (LAHNC) is concurrent chemoradiation with three‐weekly cisplatin 100 mg/m(2). However, prescribing cisplatin at this dose increases the treatment toxicity, which may compromise the treatment results. An alternat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ameri, Ahmad, Norouzi, Shokoufe, Sourati, Ainaz, Azghandi, Samira, Novin, Kambiz, Taghizadeh‐Hesary, Farzad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789619/
https://www.ncbi.nlm.nih.gov/pubmed/34101389
http://dx.doi.org/10.1002/cnr2.1425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789619/
https://www.ncbi.nlm.nih.gov/pubmed/34101389
http://dx.doi.org/10.1002/cnr2.1425

Ejemplares similares